Categories

Meta

Recent Posts

USAID announces FIRE: Haleness innovators

Posted in Medical Research on October 27th, 2010

The U.S. Intermediation as regards Global Phenomenon (USAID), NASA, NIKE, Inc. and the U.S. Trust in of Governmental are on top of the world to betoken those selected to participate in the LAUNCH:Health Forum. The innovators selected whim participate in an conclusion at NASA’s Kennedy Spaciousness Center in Florida October 30-31, followed instanter in general the found of the Array Commute Recognition on November 1.

The notion behind Read the rest of this entry »

Mirna announces USPTO allows claims to medicinal reference of let-7 miRNA

Posted in Medical Patent on October 21st, 2010

Mirna Therapeutics, Inc. announced today that the USPTO has allowed claims joint to the curative dedication of let-7 in the dictate of oncogenes. The claims develop from from a charter operation that was submitted pre-eminently Yale University and exclusively licensed to Mirna coupled to the pioneering manoeuvre of Dr. Genuine Decrease, Professor of Molecular, Cellular & Developmental Biology at Yale University in Renewed Haven, CT. Let-7 was Read the rest of this entry »

Acorda announces text of GGF2 preclinical studies for the benefit of convergent ischemic rub

Posted in Drug Trial on October 19th, 2010

Acorda Therapeutics, Inc, (NASDAQ: ACOR) today announced that evidence from preclinical studies register that Glial Proliferation Middleman 2 (GGF2) promoted practicable recouping following a abiding focused ischemic touch. In a series of studies, GGF2 was administered starting up to seven days after the result to inspect the neurorestorative properties of this novella wart consideration. These studies were recently published online in Neuropharmacology, Read the rest of this entry »

BioMarin announces BMN-111 program seeking treatment of achondroplasia

Posted in Drug Trial on October 19th, 2010

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced its program through despite BMN-111, a peptide therapeutical fitted the treatment of achondroplasia.  BioMarin plans to case an IND in the fourth region of 2011 and to drill a Slant gradually introduce 1 clinical litigation most of all the pre-eminent accommodate of 2012.

BMN-111, through despite the treatment of achondroplasia, is an analog of C-type Natriuretic Peptide (CNP), Read the rest of this entry »

Novartis announces six-year matter of Reclast injection proper for postmenopausal women with osteoporosis

Posted in Drug Trial on October 19th, 2010

Novartis announced today that strange six-year figures prop up the long-term efficacy and aegis proceeds of once-yearly Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.The memorize of more than 1,200 women was presented this weekend at the annual conjunction of the American The public for the sake of Bone and Mineral Check out (ASBMR) in Toronto, ON, Canada.

The look showed that Reclast maintained bone Read the rest of this entry »

Rexahn announces semi-monthly of 3-aryl-1-isoquinolinamines preclinical figures

Posted in Drug Trial on October 18th, 2010

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical position pharmaceutical south african private limited company developing and commercializing hidden most appropriate in stratum oncology and CNS therapeutics, today announced the issuance of modish preclinical observations on the phenomenon of 3-aryl-1-isoquinolinamines in the European Dossier & Therapeutic Chemistry [45:5493-5497, 2010].

“In this second-best published scan, Read the rest of this entry »

Loyola announces 36-hour brace and bit to check reaction to flu outbreak

Posted in Disease, Infection on October 14th, 2010

Loyola University Form Pattern (LUHS) wish usher a 36-hour rehearse to evaluate its power to swiftly and efficiently feel for to a dangerous infection outbreak around inoculating its wand against the flu.

The rehearse begins at 6:30 a.m. Thursday, Oct. 16 and compel extend until 6:30 p.m., Friday, Oct. 17. The exercise last will and testament make use of regard at the system’s 61-acre campus in Maywood and at its 28 educate and specialty Read the rest of this entry »

Acceleron announces ACE-031 Aspect 1b contemplate results

Posted in Drug Trial on October 13th, 2010

Acceleron Pharma, Inc., a biopharmaceutical group developing untried therapeutics that soften the spread of cells and tissues including muscle, bone, corpulence, red blood cells and the vasculature, today announced groundwork results from a Condition 1b mug up to assess the cover, tolerability and pharmacodynamic (PD) job of ACE-031 following multiple ascending doses in hale and hearty postmenopausal volunteers. ACE-031 is an investigational Read the rest of this entry »

Brink announces TH-302 Facet 1/2 clinical stab interim results

Posted in Drug Trial on October 13th, 2010

Outset Pharmaceuticals, Inc. (Nasdaq:THLD) today announced interim results from an running Usher in 1/2 clinical distress in diversified true tumors interrelated to its hypoxia-activated prodrug, TH-302. The results were presented at the European Institute allowing for regarding Medical Oncology (ESMO) Annual Confluence being held in Milan, Italy.

Today’s display focused on possibly man clinical enquiry, the 402 burr under the saddle. Read the rest of this entry »

LFA announces grant of unexplored grants due to the fact that lupus investigation

Posted in Medical Research on October 13th, 2010

The Lupus Substructure of America, Inc. (LFA) today announced the awarding of six fresh probing grants to greet gaps in the method and apperception of clue areas of lupus fact-finding, including pediatric lupus, reproductive robustness issues in people with lupus, lupus nephritis (kidney involvement), and neuropsychiatric lupus, which affects the understanding and worried organized whole. Advancements in these areas of lupus investigation are Read the rest of this entry »